BioWorld

Oct. 20, 2003

View Archived Issues

FDA Signs Off On Namenda For Moderate To Severe Alzheimer's

Patients suffering from a seemingly hopeless affliction, and those around them, might gain a glimmer of hope on news of the FDA's approval of Namenda (memantine HCL) for Alzheimer's disease. (BioWorld Today) Read More

President's Council Questions Biotech's Use 'Beyond Therapy'

Read More

Listeria monocytogenes Bacteria Pick, Choose, Young, Old, Pregnant As Victims Of Low-Virulence Death

Read More

Advancis IPO Raises $60M; Biotech Firms Wait In Wings

Read More

Correction

Read More

Durect Stock Falls 35 Percent On Likely Phase III Trial Delay

Read More

Genelabs Rakes In $27.4M For Prestara, Hepatitis C Programs

Read More

Other News To Note

Read More